Safety and Efficacy of Long-Term Velaglucerase Alfa Therapy in Treatment-Naïve Adults with Type 1 Gaucher Disease: Results from Phase III Trials

Authors

Pilar Giraldo
Ari Zimran
Atul Mehta
Derralynn A. Hughes
Thomas N. Hangartner, Wright State University - Main CampusFollow
Nan Wang
Gabriel M. Cohn
Eric Crombez
Deborah Elstein

Document Type

Abstract

Publication Date

2-2014

Abstract

A subgroup analysis of the safety and efficacy of velaglucerase alfa in adult patients (age ≥ 18 years) with type I Gaucher disease (GD1) who were treatment-naïve at advent of trial participation is presented.

Comments

Presented at the Lysosomal Disease Network WORLD Symposium, San Diego, CA, February 11-13, 2014.

Repository Citation

Giraldo, P., Zimran, A., Mehta, A., Hughes, D. A., Hangartner, T. N., Wang, N., Cohn, G. M., Crombez, E., & Elstein, D. (2014). Safety and Efficacy of Long-Term Velaglucerase Alfa Therapy in Treatment-Naïve Adults with Type 1 Gaucher Disease: Results from Phase III Trials. Molecular Genetics and Metabolism, 111 (2), 85, S47.
https://corescholar.libraries.wright.edu/bie/128

DOI

10.1016/j.ymgme.2013.12.097